We help plan and run virtual and live events for our clients that attract key investors, analysts and other stakeholders, including:
Company A went public two years after announcing negative Phase 3 results for its lead product candidate. Post-IPO, the Com
We help plan and run virtual and live events for our clients that attract key investors, analysts and other stakeholders, including:
Company A went public two years after announcing negative Phase 3 results for its lead product candidate. Post-IPO, the Company had a limited number of shareholders, a mixed reputation on Wall Street and pending Phase 3 data for the same product in a new indication. Thumos and its partners was retained initially to enhance visibility and awareness in advance of the announcement in the EU.
Our deep industry knowledge and research on best practices assist each client in crafting key messages. Integrating vision, the value and impact of scientific innovation, differentiation from peers, and specific expertise into a thoughtful story that resonates with investors is key to building credibility and value.
Company B was a smal
Our deep industry knowledge and research on best practices assist each client in crafting key messages. Integrating vision, the value and impact of scientific innovation, differentiation from peers, and specific expertise into a thoughtful story that resonates with investors is key to building credibility and value.
Company B was a small-cap biotechnology company that had launched a new product within the last twelve months. The product’s launch was very successful and had captured the attention of momentum, event and other “fast money” investors. While the increased trading activity created liquidity, it also exacerbated share price volatility. Company B wanted to create a more stable EU shareholder base specifically looking to add investors with longer term horizons.
We have extensive knowledge and resources to help clients identify the right healthcare and biotechnology investors. We help manage these relationships and also handle outreach and scheduling.
Company C was a development-stage industrial biotech company that had recently completed a very successful IPO in a shaky overall market. Thumos
We have extensive knowledge and resources to help clients identify the right healthcare and biotechnology investors. We help manage these relationships and also handle outreach and scheduling.
Company C was a development-stage industrial biotech company that had recently completed a very successful IPO in a shaky overall market. Thumos and its partners were responsible for heavily ramping up the IR program, to help maintain the visibility the Company had achieved through the IPO process, to get more EU investors into the stock.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.